Zacks Research Issues Pessimistic Forecast for ACHV Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Stock analysts at Zacks Research cut their FY2026 earnings estimates for shares of Achieve Life Sciences in a research note issued to investors on Tuesday, March 24th. Zacks Research analyst J. Vandermosten now expects that the biopharmaceutical company will post earnings per share of ($1.40) for the year, down from their prior estimate of ($1.07). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($0.65) EPS.

Several other research analysts have also commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Achieve Life Sciences in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.50.

Achieve Life Sciences Stock Performance

Shares of NASDAQ:ACHV opened at $2.89 on Friday. The firm has a 50 day moving average of $4.38 and a 200 day moving average of $4.29. The company has a quick ratio of 5.14, a current ratio of 4.39 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $153.83 million, a price-to-earnings ratio of -2.22 and a beta of 1.81. Achieve Life Sciences has a 52 week low of $1.84 and a 52 week high of $6.03.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Institutional Trading of Achieve Life Sciences

A number of institutional investors have recently made changes to their positions in ACHV. Franklin Resources Inc. grew its stake in Achieve Life Sciences by 18,747.4% during the 4th quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock worth $21,715,000 after buying an additional 4,346,011 shares during the last quarter. Hudson Bay Capital Management LP purchased a new stake in Achieve Life Sciences in the second quarter valued at about $2,652,000. Millennium Management LLC boosted its holdings in Achieve Life Sciences by 472.3% in the fourth quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after acquiring an additional 1,121,614 shares in the last quarter. Pathstone Holdings LLC purchased a new stake in shares of Achieve Life Sciences during the third quarter worth about $1,581,000. Finally, KVP Capital Advisors LP acquired a new position in shares of Achieve Life Sciences during the fourth quarter valued at about $2,298,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Key Achieve Life Sciences News

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and set a $12 price target, raising visibility on upside if cytisinicline gains FDA approval and commercial traction; the firm also published short‑term EPS forecasts tied to ongoing development. HC Wainwright Buy Rating
• Positive Sentiment: Unusually large retail/institutional call option purchases were reported, signaling speculative bullish positioning that can amplify near‑term upside and volatility. Investors Purchase Call Options
• Positive Sentiment: Publication in Nicotine & Tobacco Research linked cytisinicline’s receptor selectivity to low nausea and favorable tolerability — data that supports the drug’s safety profile and could aid regulatory review and prescriber adoption. GlobeNewswire Publication
• Positive Sentiment: Analyst/industry commentary highlights an upcoming FDA PDUFA date (June 20, 2026) for cytisinicline and plans to start a Phase 3 vaping‑cessation trial (ORCA‑V2) in 1H 2026 — both are key milestones that could create major value inflection points if positive. Seeking Alpha PDUFA / Vaping Expansion
• Neutral Sentiment: Company Q4 2025 earnings call and accompanying summaries reviewed program timelines, manufacturing partnerships and commercialization planning — useful for modeling but no new regulatory decision was announced on the call. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 2025 results showed a slight EPS miss (reported -$0.28 vs. consensus -$0.27) and the company remains unprofitable with negative forward EPS consensus; until regulatory approval and commercial revenue arrive, cash burn and dilution risk remain headwinds. Q4 2025 Earnings Call Transcript

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.